A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type I Diabetes Mellitus
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Diabetes-cell-therapy-Diatranz-Otsuka-Limited (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Diatranz Otsuka Limited; Living Cell Technologies
Most Recent Events
- 18 Sep 2014 New trial record